Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy
Division of Histopathology, Department of Cellular and Molecular Medicine, School of Medical Sciences and Bristol Royal Infirmary, University of Bristol, Bristol, UK.